Gyre Therapeutics (GYRE) EBT Margin Growth (3y) (2013 - 2026)

Gyre Therapeutics (GYRE) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 132.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -674,462.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 8,006.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 71,157.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -5,319.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,980.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 31,363.00
10 Gyre Therapeutics 708.31 Mn 685.47 Mn 26.90 Mn -6,955.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -6,955.00
Mar 31, 2026 -6,617.00
Dec 31, 2025 2,229.00
Mar 31, 2025 185,174.00
Dec 31, 2024 87,675.00
Sep 30, 2024 122,090.00
Jun 30, 2024 204,680.00
Mar 31, 2024 158,786.00
Dec 31, 2023 56,987.00
Sep 30, 2023 185,373.00
Jun 30, 2023 117,611.00
Mar 31, 2023 5,922.00
Mar 31, 2021 11.85 Mn
Dec 31, 2020 86,988.00
Sep 30, 2020 289.00
Jun 30, 2020 413,844.00
Mar 31, 2020 149,287.00
Mar 31, 2018 -11.91 Mn
Dec 31, 2017 -112,281.00
Sep 30, 2017 -93,523.00